NET ASSET VALUE – 30 November 2024

MARKN.

On the 30 November 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,206 million and NAV per share was SEK 53.88.



Allocation of NAV
Share of portfolio companyFair value (MSEK)Part of NAV per share (SEK)Share of NAV
Product Development    
Prokarium42%4866.2311.6%
Xspray Pharma18%2693.446.4%
KAHR Medical31%2062.644.9%
Empros Pharma79%2042.624.9%
Atrogi37%1762.254.2%
Lipum57%1712.194.1%
Microbiotica11%1381.773.3%
Geneos Therapeutics12%1051.342.5%
Xintela56%1041.342.5%
Mendus24%1011.302.4%
Toleranzia66%971.252.3%
EpiEndo Pharmaceuticals9%570.731.4%
Synerkine Pharma43%530.681.3%
AnaCardio19%520.661.2%
Egetis Therapeutics2%380.490.9%
Buzzard Pharmaceuticals14%290.370.7%
Vitara Biomedical8%290.370.7%
Sixera Pharma24%270.350.6%
Alder Therapeutics21%170.220.4%
Amarna Therapeutics58%120.150.3%
Strike Pharma16%90.110.2%
Total 2,38030.4956.6%





Commercial Growth   
NorthX Biologics92%1892.424.5%
Symcel31%1692.164.0%
Provell Pharmaceuticals72%780.991.8%
Chromafora31%730.931.7%
Nanologica43%630.811.5%
A3P Biomedical8%420.541.0%
Frontier Biosolutions2%190.240.5%
Bohus Biotech45%170.210.4%
Total 6498.3115.4%





Limited Partnerships, total 921.182.2%
     
Assets related to Portfolio companies 2993.847.1%
Other assets and liabilities 78510.0618.7%
     
Net asset value 4,20653.88100.0%
  

 

    

* indirect shares in Provell Pharmaceuticals

Datum 2024-12-03, kl 08:00
Källa MFN
Alla Aktier tipsar: Har du redan ett konto på Avanza? Varför inte skapa ett på Nordnet också och jämföra funktioner, courtage mm. Det tar inte lång tid, du fixar det direkt här med BankID
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet